The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Oncology Small Molecule Drugs Market Research Report 2025
Synopsis
Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. Cancer Treatment Drugs are used to treat malignancies, or cancerous growths.
The global Oncology Small Molecule Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Oncology Small Molecule Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Oncology Small Molecule Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Oncology Small Molecule Drugs in Blood Cancer is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Oncology Small Molecule Drugs include Roche, Novartis, Pfizer, Celgene, Bristol-Myers Squibb, Amgen, Johnson & Johnson, AbbVie and Sanofi, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Oncology Small Molecule Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Small Molecule Drugs.
Report Scope
The Oncology Small Molecule Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oncology Small Molecule Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oncology Small Molecule Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Novartis
Pfizer
Celgene
Bristol-Myers Squibb
Amgen
Johnson & Johnson
AbbVie
Sanofi
Takeda
Eli Lilly
Bayer
AstraZeneca
Astellas
Merck
Biogen Idec
Eisai
Teva
Otsuka
Ipsen
Gilead Sciences
Exelixis
Segment by Type
Chemotherapy Drugs
Immunomodulating Drugs
Targeted Therapy Drugs
Hormonal Therapy
Other
Segment by Application
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Lung Cancer
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oncology Small Molecule Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. Cancer Treatment Drugs are used to treat malignancies, or cancerous growths.
The global Oncology Small Molecule Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Oncology Small Molecule Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Oncology Small Molecule Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Oncology Small Molecule Drugs in Blood Cancer is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Oncology Small Molecule Drugs include Roche, Novartis, Pfizer, Celgene, Bristol-Myers Squibb, Amgen, Johnson & Johnson, AbbVie and Sanofi, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Oncology Small Molecule Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Small Molecule Drugs.
Report Scope
The Oncology Small Molecule Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oncology Small Molecule Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oncology Small Molecule Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Novartis
Pfizer
Celgene
Bristol-Myers Squibb
Amgen
Johnson & Johnson
AbbVie
Sanofi
Takeda
Eli Lilly
Bayer
AstraZeneca
Astellas
Merck
Biogen Idec
Eisai
Teva
Otsuka
Ipsen
Gilead Sciences
Exelixis
Segment by Type
Chemotherapy Drugs
Immunomodulating Drugs
Targeted Therapy Drugs
Hormonal Therapy
Other
Segment by Application
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Lung Cancer
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oncology Small Molecule Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oncology Small Molecule Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Chemotherapy Drugs
1.2.3 Immunomodulating Drugs
1.2.4 Targeted Therapy Drugs
1.2.5 Hormonal Therapy
1.2.6 Other
1.3 Market by Application
1.3.1 Global Oncology Small Molecule Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Blood Cancer
1.3.3 Breast Cancer
1.3.4 Gastrointestinal Cancer
1.3.5 Prostate Cancer
1.3.6 Lung Cancer
1.3.7 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oncology Small Molecule Drugs Market Perspective (2019-2030)
2.2 Oncology Small Molecule Drugs Growth Trends by Region
2.2.1 Global Oncology Small Molecule Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Oncology Small Molecule Drugs Historic Market Size by Region (2019-2024)
2.2.3 Oncology Small Molecule Drugs Forecasted Market Size by Region (2025-2030)
2.3 Oncology Small Molecule Drugs Market Dynamics
2.3.1 Oncology Small Molecule Drugs Industry Trends
2.3.2 Oncology Small Molecule Drugs Market Drivers
2.3.3 Oncology Small Molecule Drugs Market Challenges
2.3.4 Oncology Small Molecule Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oncology Small Molecule Drugs Players by Revenue
3.1.1 Global Top Oncology Small Molecule Drugs Players by Revenue (2019-2024)
3.1.2 Global Oncology Small Molecule Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Oncology Small Molecule Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Oncology Small Molecule Drugs Revenue
3.4 Global Oncology Small Molecule Drugs Market Concentration Ratio
3.4.1 Global Oncology Small Molecule Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oncology Small Molecule Drugs Revenue in 2023
3.5 Oncology Small Molecule Drugs Key Players Head office and Area Served
3.6 Key Players Oncology Small Molecule Drugs Product Solution and Service
3.7 Date of Enter into Oncology Small Molecule Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Oncology Small Molecule Drugs Breakdown Data by Type
4.1 Global Oncology Small Molecule Drugs Historic Market Size by Type (2019-2024)
4.2 Global Oncology Small Molecule Drugs Forecasted Market Size by Type (2025-2030)
5 Oncology Small Molecule Drugs Breakdown Data by Application
5.1 Global Oncology Small Molecule Drugs Historic Market Size by Application (2019-2024)
5.2 Global Oncology Small Molecule Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Oncology Small Molecule Drugs Market Size (2019-2030)
6.2 North America Oncology Small Molecule Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Oncology Small Molecule Drugs Market Size by Country (2019-2024)
6.4 North America Oncology Small Molecule Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oncology Small Molecule Drugs Market Size (2019-2030)
7.2 Europe Oncology Small Molecule Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Oncology Small Molecule Drugs Market Size by Country (2019-2024)
7.4 Europe Oncology Small Molecule Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oncology Small Molecule Drugs Market Size (2019-2030)
8.2 Asia-Pacific Oncology Small Molecule Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Oncology Small Molecule Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Oncology Small Molecule Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oncology Small Molecule Drugs Market Size (2019-2030)
9.2 Latin America Oncology Small Molecule Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Oncology Small Molecule Drugs Market Size by Country (2019-2024)
9.4 Latin America Oncology Small Molecule Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oncology Small Molecule Drugs Market Size (2019-2030)
10.2 Middle East & Africa Oncology Small Molecule Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Oncology Small Molecule Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Oncology Small Molecule Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Oncology Small Molecule Drugs Introduction
11.1.4 Roche Revenue in Oncology Small Molecule Drugs Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Oncology Small Molecule Drugs Introduction
11.2.4 Novartis Revenue in Oncology Small Molecule Drugs Business (2019-2024)
11.2.5 Novartis Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Detail
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Oncology Small Molecule Drugs Introduction
11.3.4 Pfizer Revenue in Oncology Small Molecule Drugs Business (2019-2024)
11.3.5 Pfizer Recent Development
11.4 Celgene
11.4.1 Celgene Company Detail
11.4.2 Celgene Business Overview
11.4.3 Celgene Oncology Small Molecule Drugs Introduction
11.4.4 Celgene Revenue in Oncology Small Molecule Drugs Business (2019-2024)
11.4.5 Celgene Recent Development
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Company Detail
11.5.2 Bristol-Myers Squibb Business Overview
11.5.3 Bristol-Myers Squibb Oncology Small Molecule Drugs Introduction
11.5.4 Bristol-Myers Squibb Revenue in Oncology Small Molecule Drugs Business (2019-2024)
11.5.5 Bristol-Myers Squibb Recent Development
11.6 Amgen
11.6.1 Amgen Company Detail
11.6.2 Amgen Business Overview
11.6.3 Amgen Oncology Small Molecule Drugs Introduction
11.6.4 Amgen Revenue in Oncology Small Molecule Drugs Business (2019-2024)
11.6.5 Amgen Recent Development
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Detail
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Oncology Small Molecule Drugs Introduction
11.7.4 Johnson & Johnson Revenue in Oncology Small Molecule Drugs Business (2019-2024)
11.7.5 Johnson & Johnson Recent Development
11.8 AbbVie
11.8.1 AbbVie Company Detail
11.8.2 AbbVie Business Overview
11.8.3 AbbVie Oncology Small Molecule Drugs Introduction
11.8.4 AbbVie Revenue in Oncology Small Molecule Drugs Business (2019-2024)
11.8.5 AbbVie Recent Development
11.9 Sanofi
11.9.1 Sanofi Company Detail
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Oncology Small Molecule Drugs Introduction
11.9.4 Sanofi Revenue in Oncology Small Molecule Drugs Business (2019-2024)
11.9.5 Sanofi Recent Development
11.10 Takeda
11.10.1 Takeda Company Detail
11.10.2 Takeda Business Overview
11.10.3 Takeda Oncology Small Molecule Drugs Introduction
11.10.4 Takeda Revenue in Oncology Small Molecule Drugs Business (2019-2024)
11.10.5 Takeda Recent Development
11.11 Eli Lilly
11.11.1 Eli Lilly Company Detail
11.11.2 Eli Lilly Business Overview
11.11.3 Eli Lilly Oncology Small Molecule Drugs Introduction
11.11.4 Eli Lilly Revenue in Oncology Small Molecule Drugs Business (2019-2024)
11.11.5 Eli Lilly Recent Development
11.12 Bayer
11.12.1 Bayer Company Detail
11.12.2 Bayer Business Overview
11.12.3 Bayer Oncology Small Molecule Drugs Introduction
11.12.4 Bayer Revenue in Oncology Small Molecule Drugs Business (2019-2024)
11.12.5 Bayer Recent Development
11.13 AstraZeneca
11.13.1 AstraZeneca Company Detail
11.13.2 AstraZeneca Business Overview
11.13.3 AstraZeneca Oncology Small Molecule Drugs Introduction
11.13.4 AstraZeneca Revenue in Oncology Small Molecule Drugs Business (2019-2024)
11.13.5 AstraZeneca Recent Development
11.14 Astellas
11.14.1 Astellas Company Detail
11.14.2 Astellas Business Overview
11.14.3 Astellas Oncology Small Molecule Drugs Introduction
11.14.4 Astellas Revenue in Oncology Small Molecule Drugs Business (2019-2024)
11.14.5 Astellas Recent Development
11.15 Merck
11.15.1 Merck Company Detail
11.15.2 Merck Business Overview
11.15.3 Merck Oncology Small Molecule Drugs Introduction
11.15.4 Merck Revenue in Oncology Small Molecule Drugs Business (2019-2024)
11.15.5 Merck Recent Development
11.16 Biogen Idec
11.16.1 Biogen Idec Company Detail
11.16.2 Biogen Idec Business Overview
11.16.3 Biogen Idec Oncology Small Molecule Drugs Introduction
11.16.4 Biogen Idec Revenue in Oncology Small Molecule Drugs Business (2019-2024)
11.16.5 Biogen Idec Recent Development
11.17 Eisai
11.17.1 Eisai Company Detail
11.17.2 Eisai Business Overview
11.17.3 Eisai Oncology Small Molecule Drugs Introduction
11.17.4 Eisai Revenue in Oncology Small Molecule Drugs Business (2019-2024)
11.17.5 Eisai Recent Development
11.18 Teva
11.18.1 Teva Company Detail
11.18.2 Teva Business Overview
11.18.3 Teva Oncology Small Molecule Drugs Introduction
11.18.4 Teva Revenue in Oncology Small Molecule Drugs Business (2019-2024)
11.18.5 Teva Recent Development
11.19 Otsuka
11.19.1 Otsuka Company Detail
11.19.2 Otsuka Business Overview
11.19.3 Otsuka Oncology Small Molecule Drugs Introduction
11.19.4 Otsuka Revenue in Oncology Small Molecule Drugs Business (2019-2024)
11.19.5 Otsuka Recent Development
11.20 Ipsen
11.20.1 Ipsen Company Detail
11.20.2 Ipsen Business Overview
11.20.3 Ipsen Oncology Small Molecule Drugs Introduction
11.20.4 Ipsen Revenue in Oncology Small Molecule Drugs Business (2019-2024)
11.20.5 Ipsen Recent Development
11.21 Gilead Sciences
11.21.1 Gilead Sciences Company Detail
11.21.2 Gilead Sciences Business Overview
11.21.3 Gilead Sciences Oncology Small Molecule Drugs Introduction
11.21.4 Gilead Sciences Revenue in Oncology Small Molecule Drugs Business (2019-2024)
11.21.5 Gilead Sciences Recent Development
11.22 Exelixis
11.22.1 Exelixis Company Detail
11.22.2 Exelixis Business Overview
11.22.3 Exelixis Oncology Small Molecule Drugs Introduction
11.22.4 Exelixis Revenue in Oncology Small Molecule Drugs Business (2019-2024)
11.22.5 Exelixis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Oncology Small Molecule Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Chemotherapy Drugs
Table 3. Key Players of Immunomodulating Drugs
Table 4. Key Players of Targeted Therapy Drugs
Table 5. Key Players of Hormonal Therapy
Table 6. Key Players of Other
Table 7. Global Oncology Small Molecule Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Oncology Small Molecule Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 9. Global Oncology Small Molecule Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 10. Global Oncology Small Molecule Drugs Market Share by Region (2019-2024)
Table 11. Global Oncology Small Molecule Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 12. Global Oncology Small Molecule Drugs Market Share by Region (2025-2030)
Table 13. Oncology Small Molecule Drugs Market Trends
Table 14. Oncology Small Molecule Drugs Market Drivers
Table 15. Oncology Small Molecule Drugs Market Challenges
Table 16. Oncology Small Molecule Drugs Market Restraints
Table 17. Global Oncology Small Molecule Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 18. Global Oncology Small Molecule Drugs Market Share by Players (2019-2024)
Table 19. Global Top Oncology Small Molecule Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Small Molecule Drugs as of 2023)
Table 20. Ranking of Global Top Oncology Small Molecule Drugs Companies by Revenue (US$ Million) in 2023
Table 21. Global 5 Largest Players Market Share by Oncology Small Molecule Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Oncology Small Molecule Drugs Product Solution and Service
Table 24. Date of Enter into Oncology Small Molecule Drugs Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Oncology Small Molecule Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 27. Global Oncology Small Molecule Drugs Revenue Market Share by Type (2019-2024)
Table 28. Global Oncology Small Molecule Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 29. Global Oncology Small Molecule Drugs Revenue Market Share by Type (2025-2030)
Table 30. Global Oncology Small Molecule Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 31. Global Oncology Small Molecule Drugs Revenue Market Share by Application (2019-2024)
Table 32. Global Oncology Small Molecule Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 33. Global Oncology Small Molecule Drugs Revenue Market Share by Application (2025-2030)
Table 34. North America Oncology Small Molecule Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. North America Oncology Small Molecule Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 36. North America Oncology Small Molecule Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 37. Europe Oncology Small Molecule Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 38. Europe Oncology Small Molecule Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 39. Europe Oncology Small Molecule Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 40. Asia-Pacific Oncology Small Molecule Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 41. Asia-Pacific Oncology Small Molecule Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 42. Asia-Pacific Oncology Small Molecule Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 43. Latin America Oncology Small Molecule Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Latin America Oncology Small Molecule Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 45. Latin America Oncology Small Molecule Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 46. Middle East & Africa Oncology Small Molecule Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 47. Middle East & Africa Oncology Small Molecule Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 48. Middle East & Africa Oncology Small Molecule Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 49. Roche Company Detail
Table 50. Roche Business Overview
Table 51. Roche Oncology Small Molecule Drugs Product
Table 52. Roche Revenue in Oncology Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 53. Roche Recent Development
Table 54. Novartis Company Detail
Table 55. Novartis Business Overview
Table 56. Novartis Oncology Small Molecule Drugs Product
Table 57. Novartis Revenue in Oncology Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 58. Novartis Recent Development
Table 59. Pfizer Company Detail
Table 60. Pfizer Business Overview
Table 61. Pfizer Oncology Small Molecule Drugs Product
Table 62. Pfizer Revenue in Oncology Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 63. Pfizer Recent Development
Table 64. Celgene Company Detail
Table 65. Celgene Business Overview
Table 66. Celgene Oncology Small Molecule Drugs Product
Table 67. Celgene Revenue in Oncology Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 68. Celgene Recent Development
Table 69. Bristol-Myers Squibb Company Detail
Table 70. Bristol-Myers Squibb Business Overview
Table 71. Bristol-Myers Squibb Oncology Small Molecule Drugs Product
Table 72. Bristol-Myers Squibb Revenue in Oncology Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 73. Bristol-Myers Squibb Recent Development
Table 74. Amgen Company Detail
Table 75. Amgen Business Overview
Table 76. Amgen Oncology Small Molecule Drugs Product
Table 77. Amgen Revenue in Oncology Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 78. Amgen Recent Development
Table 79. Johnson & Johnson Company Detail
Table 80. Johnson & Johnson Business Overview
Table 81. Johnson & Johnson Oncology Small Molecule Drugs Product
Table 82. Johnson & Johnson Revenue in Oncology Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 83. Johnson & Johnson Recent Development
Table 84. AbbVie Company Detail
Table 85. AbbVie Business Overview
Table 86. AbbVie Oncology Small Molecule Drugs Product
Table 87. AbbVie Revenue in Oncology Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 88. AbbVie Recent Development
Table 89. Sanofi Company Detail
Table 90. Sanofi Business Overview
Table 91. Sanofi Oncology Small Molecule Drugs Product
Table 92. Sanofi Revenue in Oncology Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 93. Sanofi Recent Development
Table 94. Takeda Company Detail
Table 95. Takeda Business Overview
Table 96. Takeda Oncology Small Molecule Drugs Product
Table 97. Takeda Revenue in Oncology Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 98. Takeda Recent Development
Table 99. Eli Lilly Company Detail
Table 100. Eli Lilly Business Overview
Table 101. Eli Lilly Oncology Small Molecule Drugs Product
Table 102. Eli Lilly Revenue in Oncology Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 103. Eli Lilly Recent Development
Table 104. Bayer Company Detail
Table 105. Bayer Business Overview
Table 106. Bayer Oncology Small Molecule Drugs Product
Table 107. Bayer Revenue in Oncology Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 108. Bayer Recent Development
Table 109. AstraZeneca Company Detail
Table 110. AstraZeneca Business Overview
Table 111. AstraZeneca Oncology Small Molecule Drugs Product
Table 112. AstraZeneca Revenue in Oncology Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 113. AstraZeneca Recent Development
Table 114. Astellas Company Detail
Table 115. Astellas Business Overview
Table 116. Astellas Oncology Small Molecule Drugs Product
Table 117. Astellas Revenue in Oncology Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 118. Astellas Recent Development
Table 119. Merck Company Detail
Table 120. Merck Business Overview
Table 121. Merck Oncology Small Molecule Drugs Product
Table 122. Merck Revenue in Oncology Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 123. Merck Recent Development
Table 124. Biogen Idec Company Detail
Table 125. Biogen Idec Business Overview
Table 126. Biogen Idec Oncology Small Molecule Drugs Product
Table 127. Biogen Idec Revenue in Oncology Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 128. Biogen Idec Recent Development
Table 129. Eisai Company Detail
Table 130. Eisai Business Overview
Table 131. Eisai Oncology Small Molecule Drugs Product
Table 132. Eisai Revenue in Oncology Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 133. Eisai Recent Development
Table 134. Teva Company Detail
Table 135. Teva Business Overview
Table 136. Teva Oncology Small Molecule Drugs Product
Table 137. Teva Revenue in Oncology Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 138. Teva Recent Development
Table 139. Otsuka Company Detail
Table 140. Otsuka Business Overview
Table 141. Otsuka Oncology Small Molecule Drugs Product
Table 142. Otsuka Revenue in Oncology Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 143. Otsuka Recent Development
Table 144. Ipsen Company Detail
Table 145. Ipsen Business Overview
Table 146. Ipsen Oncology Small Molecule Drugs Product
Table 147. Ipsen Revenue in Oncology Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 148. Ipsen Recent Development
Table 149. Gilead Sciences Company Detail
Table 150. Gilead Sciences Business Overview
Table 151. Gilead Sciences Oncology Small Molecule Drugs Product
Table 152. Gilead Sciences Revenue in Oncology Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 153. Gilead Sciences Recent Development
Table 154. Exelixis Company Detail
Table 155. Exelixis Business Overview
Table 156. Exelixis Oncology Small Molecule Drugs Product
Table 157. Exelixis Revenue in Oncology Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 158. Exelixis Recent Development
Table 159. Research Programs/Design for This Report
Table 160. Key Data Information from Secondary Sources
Table 161. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Oncology Small Molecule Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Oncology Small Molecule Drugs Market Share by Type: 2023 VS 2030
Figure 3. Chemotherapy Drugs Features
Figure 4. Immunomodulating Drugs Features
Figure 5. Targeted Therapy Drugs Features
Figure 6. Hormonal Therapy Features
Figure 7. Other Features
Figure 8. Global Oncology Small Molecule Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 9. Global Oncology Small Molecule Drugs Market Share by Application: 2023 VS 2030
Figure 10. Blood Cancer Case Studies
Figure 11. Breast Cancer Case Studies
Figure 12. Gastrointestinal Cancer Case Studies
Figure 13. Prostate Cancer Case Studies
Figure 14. Lung Cancer Case Studies
Figure 15. Other Case Studies
Figure 16. Oncology Small Molecule Drugs Report Years Considered
Figure 17. Global Oncology Small Molecule Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 18. Global Oncology Small Molecule Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 19. Global Oncology Small Molecule Drugs Market Share by Region: 2023 VS 2030
Figure 20. Global Oncology Small Molecule Drugs Market Share by Players in 2023
Figure 21. Global Top Oncology Small Molecule Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Small Molecule Drugs as of 2023)
Figure 22. The Top 10 and 5 Players Market Share by Oncology Small Molecule Drugs Revenue in 2023
Figure 23. North America Oncology Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. North America Oncology Small Molecule Drugs Market Share by Country (2019-2030)
Figure 25. United States Oncology Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Canada Oncology Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Europe Oncology Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Europe Oncology Small Molecule Drugs Market Share by Country (2019-2030)
Figure 29. Germany Oncology Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. France Oncology Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. U.K. Oncology Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Italy Oncology Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Russia Oncology Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Nordic Countries Oncology Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Asia-Pacific Oncology Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Asia-Pacific Oncology Small Molecule Drugs Market Share by Region (2019-2030)
Figure 37. China Oncology Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Japan Oncology Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. South Korea Oncology Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Southeast Asia Oncology Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. India Oncology Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Australia Oncology Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Latin America Oncology Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Latin America Oncology Small Molecule Drugs Market Share by Country (2019-2030)
Figure 45. Mexico Oncology Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Brazil Oncology Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Oncology Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa Oncology Small Molecule Drugs Market Share by Country (2019-2030)
Figure 49. Turkey Oncology Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Saudi Arabia Oncology Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 51. Roche Revenue Growth Rate in Oncology Small Molecule Drugs Business (2019-2024)
Figure 52. Novartis Revenue Growth Rate in Oncology Small Molecule Drugs Business (2019-2024)
Figure 53. Pfizer Revenue Growth Rate in Oncology Small Molecule Drugs Business (2019-2024)
Figure 54. Celgene Revenue Growth Rate in Oncology Small Molecule Drugs Business (2019-2024)
Figure 55. Bristol-Myers Squibb Revenue Growth Rate in Oncology Small Molecule Drugs Business (2019-2024)
Figure 56. Amgen Revenue Growth Rate in Oncology Small Molecule Drugs Business (2019-2024)
Figure 57. Johnson & Johnson Revenue Growth Rate in Oncology Small Molecule Drugs Business (2019-2024)
Figure 58. AbbVie Revenue Growth Rate in Oncology Small Molecule Drugs Business (2019-2024)
Figure 59. Sanofi Revenue Growth Rate in Oncology Small Molecule Drugs Business (2019-2024)
Figure 60. Takeda Revenue Growth Rate in Oncology Small Molecule Drugs Business (2019-2024)
Figure 61. Eli Lilly Revenue Growth Rate in Oncology Small Molecule Drugs Business (2019-2024)
Figure 62. Bayer Revenue Growth Rate in Oncology Small Molecule Drugs Business (2019-2024)
Figure 63. AstraZeneca Revenue Growth Rate in Oncology Small Molecule Drugs Business (2019-2024)
Figure 64. Astellas Revenue Growth Rate in Oncology Small Molecule Drugs Business (2019-2024)
Figure 65. Merck Revenue Growth Rate in Oncology Small Molecule Drugs Business (2019-2024)
Figure 66. Biogen Idec Revenue Growth Rate in Oncology Small Molecule Drugs Business (2019-2024)
Figure 67. Eisai Revenue Growth Rate in Oncology Small Molecule Drugs Business (2019-2024)
Figure 68. Teva Revenue Growth Rate in Oncology Small Molecule Drugs Business (2019-2024)
Figure 69. Otsuka Revenue Growth Rate in Oncology Small Molecule Drugs Business (2019-2024)
Figure 70. Ipsen Revenue Growth Rate in Oncology Small Molecule Drugs Business (2019-2024)
Figure 71. Gilead Sciences Revenue Growth Rate in Oncology Small Molecule Drugs Business (2019-2024)
Figure 72. Exelixis Revenue Growth Rate in Oncology Small Molecule Drugs Business (2019-2024)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
